Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients.

Garg MB, Sakoff JA, Ackland SP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2201-5. doi: 10.1016/j.jchromb.2011.06.001. Epub 2011 Jun 13.

PMID:
21719363
[PubMed - indexed for MEDLINE]
2.

Determination of mitotane (o,p-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high-performance liquid chromatography.

Andersen A, Kasperlik-Zaluska AA, Warren DJ.

Ther Drug Monit. 1999 Jun;21(3):355-9.

PMID:
10365653
[PubMed - indexed for MEDLINE]
3.
4.

Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.

Kasperlik-Zaluska AA, Cichocki A.

J Exp Ther Oncol. 2005;5(2):125-32.

PMID:
16471038
[PubMed - indexed for MEDLINE]
5.

Use of GC/MS/SIM for rapid determination of plasma levels of o,p'-DDD, o,p'-DDE and o,p'-DDA.

Inouye M, Mio T, Sumino K.

Clin Chim Acta. 1987 Dec;170(2-3):305-14.

PMID:
3436064
[PubMed - indexed for MEDLINE]
6.

[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].

Heilmann P, Wagner P, Nawroth PP, Ziegler R.

Med Klin (Munich). 2001 Jul 15;96(7):371-7. German.

PMID:
11494911
[PubMed - indexed for MEDLINE]
7.

o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.

Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC.

Cancer. 1978 Nov;42(5):2177-81.

PMID:
719602
[PubMed - indexed for MEDLINE]
8.

Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.

Cai W, Benitez R, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL.

Biochem Pharmacol. 1995 May 17;49(10):1483-9.

PMID:
7763292
[PubMed - indexed for MEDLINE]
9.

Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs.

Hermansson V, Cantillana T, Hovander L, Bergman A, Ljungvall K, Magnusson U, Törneke K, Brandt I.

Cancer Chemother Pharmacol. 2008 Feb;61(2):267-74. Epub 2007 Apr 12.

PMID:
17431626
[PubMed - indexed for MEDLINE]
10.

Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.

Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, Toscano V, Stigliano A.

Endocr Relat Cancer. 2008 Jun;15(2):623-34. doi: 10.1677/erc.1.1315.

PMID:
18509009
[PubMed - indexed for MEDLINE]
Free Article
11.

Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells.

Hermansson V, Asp V, Bergman A, Bergström U, Brandt I.

Arch Toxicol. 2007 Nov;81(11):793-801. Epub 2007 May 9.

PMID:
17487473
[PubMed - indexed for MEDLINE]
12.

Metabolism of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane and 1,1-dichloro-2,2-bis(p-chlorophenyl)ethane in the mouse.

Gold B, Brunk G.

Chem Biol Interact. 1982 Sep;41(3):327-39.

PMID:
7105253
[PubMed - indexed for MEDLINE]
13.

Metabolism of 1-(0-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) in rats.

Reif VD, Sinsheimer JE.

Drug Metab Dispos. 1975 Jan-Feb;3(1):15-25.

PMID:
234830
[PubMed - indexed for MEDLINE]
14.

[Metabolism of o,p'-DDD (mitotane) in human and animals. Actual notions and practical deductions (author's transl)].

Touitou Y, Bogdan A, Legrand JC, Desgrez P.

Ann Endocrinol (Paris). 1977;38(1):13-25. Review. French.

PMID:
324349
[PubMed - indexed for MEDLINE]
15.

Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.

Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D.

Cancer Chemother Pharmacol. 1981;7(1):51-4.

PMID:
7340988
[PubMed - indexed for MEDLINE]
16.

Metabolic activation and binding of mitotane in adrenal cortex homogenates.

Cai W, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL.

J Pharm Sci. 1995 Feb;84(2):134-8.

PMID:
7738789
[PubMed - indexed for MEDLINE]
17.

Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.

Lindhe O, Skogseid B.

Horm Metab Res. 2010 Sep;42(10):725-30. doi: 10.1055/s-0030-1261923. Epub 2010 Jul 27.

PMID:
20665429
[PubMed - indexed for MEDLINE]
18.

Transcriptional activation of the human estrogen receptor by DDT isomers and metabolites in yeast and MCF-7 cells.

Chen CW, Hurd C, Vorojeikina DP, Arnold SF, Notides AC.

Biochem Pharmacol. 1997 Apr 25;53(8):1161-72.

PMID:
9175721
[PubMed - indexed for MEDLINE]
19.

Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis.

Lindhe O, Skogseid B, Brandt I.

J Clin Endocrinol Metab. 2002 Mar;87(3):1319-26.

PMID:
11889204
[PubMed - indexed for MEDLINE]
20.

Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.

Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E.

J Clin Endocrinol Metab. 2011 Jun;96(6):1844-51. doi: 10.1210/jc.2010-2676. Epub 2011 Apr 6.

PMID:
21470991
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk